In a Methotrexate-Induced Model of Intestinal Mucositis, Olmesartan Reduced Inflammation and Induced Enteropathy Characterized by Severe Diarrhea, Weight Loss, and Reduced Sucrose Activity

dc.contributor.authorAraújo, Aurigena Antunes de
dc.contributor.authorBorba, Pedro Brito
dc.contributor.authorSouza, Fernando Henrique Destefani de
dc.contributor.authorNogueira, Anália Cristina
dc.contributor.authorSaldanha, Taís Suassuna
dc.contributor.authorAraújo, Thayse Emanuele Franklin
dc.contributor.authorSilva, Aldemara Ingrid da
dc.contributor.authorAraújo Júnior, Raimundo Fernandes de
dc.date.accessioned2018-06-16T12:36:20Z
dc.date.available2018-06-16T12:36:20Z
dc.date.issued2015
dc.description.resumoThe aim of this study was to evaluate the effect of olmesartan (OLME), an angiotensin II receptor antagonist, on an intestinal mucositis model. Briefly, daily intraperitoneal (i.p.) injections of methotrexate (MTX) 7 mg/kg were administered to rats on 3 consecutive days. A subset of these rats was also pretreated with oral administration of OLME (0.5, 1.0, or 5.0 mg/kg) or vehicle as a control 30 min prior to MTX injection. Body weight, feces scoring, and death were recorded daily. On day 4, the rats were killed, and intestinal tissues were assayed for levels of interleukin (IL)-1β and tumor necrosis factor (TNF)-α, myeloperoxidase and sucrose activity, and histopathological findings. A significant reduction in body weight was observed in the MTX+1.0 mg/kg OLME group (p<0.01). The feces scores for the MTX+0.5 mg/kg OLME and MTX+5.0 mg/kg OLME groups were also significantly higher (p<0.001). Sucrose activity was reduced in all groups treated with OLME (p<0.05). Treatment with MTX+OLM at all doses resulted in reduced inflammatory infiltration, ulcerations, vasodilation, and hemorrhagic areas (p<0.05), as well as reduced concentrations of myeloperoxidase (p<0.001). The IL-1β and TNF-α levels were decreased in the MTX+OLME 5.0 mg/kg (p<0.01 and p<0.05, respectively) compared with the MTX-alone group. Overall, antiinflammatory activity was observed in rats with MTX-induced intestinal mucositis that were administered OLME. However, further studies are needed to elucidate the adverse effects of OLME.pt_BR
dc.identifier.citationARAÚJO, Aurigena Antunes de et al. In a Methotrexate-Induced Model of Intestinal Mucositis, Olmesartan Reduced Inflammation and Induced Enteropathy Characterized by Severe Diarrhea, Weight Loss, and Reduced Sucrose Activity. Biological & Pharmaceutical Bulletin, v. 38, p. 746-752, 2015. Disponível em: <https://www.jstage.jst.go.jp/article/bpb/38/5/38_b14-00847/_article>. Acesso em: 20 mar. 2018.pt_BR
dc.identifier.doihttps://doi.org/10.1248/bpb.b14-00847
dc.identifier.issn1347-5215
dc.identifier.urihttps://repositorio.ufrn.br/jspui/handle/123456789/25429
dc.languageengpt_BR
dc.publisherThe Pharmaceutical Society of Japanpt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectintestinal mucositis modelpt_BR
dc.subjectolmesartanpt_BR
dc.subjectinflammationpt_BR
dc.titleIn a Methotrexate-Induced Model of Intestinal Mucositis, Olmesartan Reduced Inflammation and Induced Enteropathy Characterized by Severe Diarrhea, Weight Loss, and Reduced Sucrose Activitypt_BR
dc.typearticlept_BR

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
Methotrexate-InducedModel_Araujo_2015.pdf
Tamanho:
3.68 MB
Formato:
Adobe Portable Document Format
Nenhuma Miniatura disponível
Baixar

Licença do Pacote

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Nenhuma Miniatura disponível
Baixar